Why is Glenmark Pharma falling/rising?

As of 14-Aug, Glenmark Pharmaceuticals Ltd. is currently priced at 2,038.95, reflecting an increase of 10.1 (0.5%). The stock has shown a mixed performance recently, with a 1-week decline of 1.52% and a 1-month drop of 8.08%. However, it has outperformed the sector today by 0.38%, and its delivery volume has increased significantly by 46.83% compared to the 5-day average, indicating rising investor participation. The stock is trading above its 50-day, 100-day, and 200-day moving averages, although it is below the 5-day and 20-day moving averages. Notably, the company has demonstrated strong financial health with a low Debt to EBITDA ratio of 1.00 times and has reported positive results for the last four consecutive quarters, contributing to a robust return of 36.74% over the past year.
In the broader market context, while Glenmark Pharmaceuticals has experienced a decline in the short term, it has significantly outperformed the benchmark Sensex, which has only increased by 3.15% year-to-date. The stock's strong institutional holdings at 38.3% suggest confidence from knowledgeable investors, and its consistent returns over the last three years further support its stability. The company's fair valuation, indicated by a Price to Book Value of 6.5 and a low PEG ratio of 0.2, suggests that it is trading at a discount compared to its peers, which may attract more investors looking for value. Overall, the combination of positive financial metrics and strong investor interest is contributing to the stock's recent upward movement despite its recent short-term fluctuations.